Navigation Links
Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography

SAN ANTONIO, June 7, 2011 /PRNewswire/ -- Presented today at the Society of Nuclear Medicine 2011 Annual Meeting researchers from Swedish Medical Center and the University of Washington showed that FDG dose for Positron Emission Mammography (PEM) may be reduced by at least 50% without altering image quality.

PEM is the breast application of the Naviscan high-resolution PET scanner showing the location as well as the metabolic phase of a lesion.  The metabolic view assists physicians in making the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term "specificity."  PEM is different than x-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease and aid in treatment planning in a patient already diagnosed with a primary breast cancer.

"With our limited clinical experience with invasive ductal carcinomas to date the clinical diagnostic quality of images appear equivalent between the 5 millicurie (mCi) dose and the traditional 10 millicurie dose. However the longer uptake time (90-120 minutes) we believe significantly improves lesion to background ratio with our invasive ductal carcinomas," stated Dr. James Rogers, a nuclear medicine physician at Seattle Nuclear Medicine and co-author of the study. "The tradeoff between lowering dose and minimally increasing imaging scan time from a 7 to 10 minute scan appears to be a reasonable imaging strategy. We are still formulating our opinion and strategy in regard to lower FDG doses that are less than 5 millicuries, and are hopeful that an individualized patient strategy based on patient weight will allow us to show that lower FDG doses will be possible for a large number of our patients.  We have not done enough DCIS only patients or Invasive Lobular patients to make a conclusion at this time."

The researchers presented results of a study to detect lesions with very low doses of radiation using the Naviscan high-resolution PET scanner.  Preliminary results from five patients with invasive ductal carcinoma as well as phantom images show that PEM lesion detection at a 5 mCi injected dose of FDG, or 50% lower than the dose commonly used in clinical practice, yielded comparable sensitivity while maintaining lesion detectability.  Preliminary results also revealed that injected dose could be reduced further for lighter patients or with concordant increased scan time. These results are part of an ongoing clinical trial at Swedish Medical Center with the goal of determining the lowest optimized dose levels of FDG required to produce high quality PEM images in patients with breast cancer.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit

For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Finds Patient Adherence to Statin Medications Reduces Hospitalizations and Healthcare Costs
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
5. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
6. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
7. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
10. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
11. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
Breaking Medicine News(10 mins):